Last years pre-IPO valuation of 700 billion won ��There is a big factor that worsens two-seam in the bio sector.�� [Edaily Reporter Kim Yu-rim] Voronoi, which is challenging the unicorn (company with excellent market evaluation) special listing No. 1, recorded poor performance in demand forecasting and withdrew its listing. Voronoi said, “Considering the market stabilization time in the future, we plan to try again for listing.” Voronoi CEO Dae-Kwon Kim giving a presentation at the IPO press conference. (Photo = Voronoi) According to the electronic disclosure system of the Financial Supervisory Service on the 16th, Voronoi decided to withdraw from listing on the KOSDAQ. Earlier, Voronoi conducted a demand forecast for institutional investors for two days from the 14th to the 15th. Voronoi raised a total of 2 million shares through this public offering. The expected public offering price was 50,000 won to 65,000 won, with a market cap of 666.7 billion won to 866.7 billion won. A Voronoi official said, “In consideration of various circumstances, such as difficulties in accurately assessing our companys corporate value in the recent high volatility market environment, we canceled the remaining schedule and submitted a withdrawal report.” The decisive reason for Voronois withdrawal is presumed to be that the IPO price was lower than the valuations of financial investors who came in just before the listing. It is known that Voronoi was valued at 700 billion won at the time of its pre-IPO (investment attraction before listing) last year. If the public offering price is set at a price lower than 700 billion won, some financial investors will not be able to recover their funds. The head of the stock management division of an asset management company said, ��It is true that the mood in the Voronoi demand forecast was not good yesterday. There are several factors, but the biggest factor is that they are investing conservatively as accidents occur one after another in sectors such as Shillajen and Osstem Implant. do,�� he analyzed. Voronoi eventually failed to challenge the first unicorn special listing. The Unicorn Special Listing is a system introduced to simplify the technology evaluation process for high-quality technology companies with excellent corporate value among unlisted companies. Technology special listing, which is the usual special listing method of biotech, must pass the examination by two evaluation institutions designated by the exchange. On the other hand, those with a market capitalization of 500 billion won or more receive the benefit of being evaluated (A or higher) by one institution designated by the exchange. Dae-Kwon Kim, CEO of Voronoi, said, ��I would like to thank the investors for showing great interest in Voronoi despite the recent chaotic market atmosphere. Considering the timing, we plan to try again for listing.��
